C WorldWide Group Holding A S Reduces Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

C WorldWide Group Holding A S decreased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 22.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 105,809 shares of the company’s stock after selling 30,000 shares during the quarter. C WorldWide Group Holding A S owned about 0.37% of Krystal Biotech worth $16,576,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Crossmark Global Holdings Inc. boosted its holdings in Krystal Biotech by 5.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock valued at $362,000 after acquiring an additional 121 shares during the period. Perigon Wealth Management LLC boosted its holdings in Krystal Biotech by 1.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock valued at $1,200,000 after acquiring an additional 123 shares during the period. KBC Group NV boosted its holdings in Krystal Biotech by 25.9% during the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock valued at $117,000 after acquiring an additional 132 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Krystal Biotech by 3.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company’s stock valued at $840,000 after acquiring an additional 153 shares during the period. Finally, Pier 88 Investment Partners LLC boosted its holdings in Krystal Biotech by 5.1% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 3,530 shares of the company’s stock valued at $643,000 after acquiring an additional 170 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This represents a 1.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 14.10% of the company’s stock.

Analyst Upgrades and Downgrades

KRYS has been the subject of a number of recent analyst reports. Citigroup boosted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday, February 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday. Finally, Chardan Capital lifted their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $210.00.

Krystal Biotech Trading Up 2.9 %

KRYS opened at $187.86 on Monday. The firm has a market cap of $5.41 billion, a price-to-earnings ratio of 62.83 and a beta of 0.84. Krystal Biotech, Inc. has a 12 month low of $107.50 and a 12 month high of $219.34. The stock has a fifty day moving average price of $157.85 and a 200-day moving average price of $175.26.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business’s revenue for the quarter was up 116.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.30 EPS. On average, equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).